Nidhi Bansal

Dr. Nidhi Bansal

Mount Sinai hospital, NY, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2014 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
JRJulie A. Reisz
Julie A. Reisz
NBNidhi Bansal
Nidhi Bansal
JQJiang Qian
Jiang Qian
WZWeiling Zhao
Weiling Zhao
CFCristina Maria Furdui
Cristina Maria Furdui
Significance: The detrimental effects of ionizing radiation (IR) involve a highly orchestrated series of events that are amplified by endogenous signaling and culminating in oxidative damage to DNA, lipids, proteins, and many metabolites. Despite the global impact of IR, the molecular mechanisms underlying tissue damage reveal that many biomolecules are chemoselectively modified by IR. Recent Advances: The development of high-throughput “omics” technologies for mapping DNA and protein modifications have revolutionized the study of IR effects on biological systems. Studies in cells, tissues, and biological fluids are used to identify molecular features or biomarkers of IR exposure and response and the molecular mechanisms that regulate their expression or synthesis. Critical Issues: In this review, chemical mechanisms are described for IR-induced modifications of biomolecules along with methods for their detection. Included with the detection methods are crucial experimental considerations and caveats for their use. Additional factors critical to the cellular response to radiation, including alterations in protein expression, metabolomics, and epigenetic factors, are also discussed. Future Directions: Throughout the review, the synergy of combined “omics” technologies such as genomics and epigenomics, proteomics, and metabolomics is highlighted. These are anticipated to lead to new hypotheses to understand IR effects on biological systems and improve IR-based therapies. Antioxid. Redox Signal. 21: 260–292.

1 August 2013 in European Journal of Cell Biology
Verified
Journal Article
Closed access
RKRama Kadamb
Rama Kadamb
SMShilpi Mittal
Shilpi Mittal
NBNidhi Bansal
Nidhi Bansal
HBHarish Batra
Harish Batra
DSDaman Saluja
Daman Saluja

2 December 2018 in Journal of Neuroscience Research
Verified
Journal Article
Open access
PDF file
EPEric M. Prager
Eric M. Prager
KCKaren E. Chambers
Karen E. Chambers
JPJoshua L. Plotkin
Joshua L. Plotkin
DMDavid L. McArthur
David L. McArthur
ABAnita Bandrowski
Anita Bandrowski
CGChris Graf
Chris Graf
Progress in basic and clinical research is slowed when researchers fail to provide a complete and accurate report of how a study was designed, executed, and the results analyzed. Publishing rigorous scientific research involves a full description of the methods, materials, procedures, and outcomes. Investigators may fail to provide a complete description of how their study was designed and executed because they may not know how to accurately report the information or the mechanisms are not in place to facilitate transparent reporting. Here, we provide an overview of how authors can write manuscripts in a transparent and thorough manner. We introduce a set of reporting criteria that can be used for publishing, including recommendations on reporting the experimental design and statistical approaches. We also discuss how to accurately visualize the results and provide recommendations for peer reviewers to enhance rigor and transparency. Incorporating transparency practices into research manuscripts will significantly improve the reproducibility of the results by independent laboratories.

1 August 2015 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YKYeon-Jin Kwon
Yeon-Jin Kwon
KPKevin Petrie
Kevin Petrie
BLBoris A Leibovitch
Boris A Leibovitch
LZLei Zeng
Lei Zeng
MMMihaly Mezei
Mihaly Mezei
SWSamuel Waxman
Samuel Waxman
Triple-negative breast cancers (TNBC) lacking estrogen, progesterone, and HER2 receptors account for 10% to 20% of breast cancer and are indicative of poor prognosis. The development of effective treatment strategies therefore represents a pressing unmet clinical need. We previously identified a molecularly targeted approach to target aberrant epigenetics of TNBC using a peptide corresponding to the SIN3 interaction domain (SID) of MAD. SID peptide selectively blocked binding of SID-containing proteins to the paired α-helix (PAH2) domain of SIN3, resulting in epigenetic and transcriptional modulation of genes associated with epithelial–mesenchymal transition (EMT). To find small molecule inhibitor (SMI) mimetics of SID peptide, we performed an in silico screen for PAH2 domain–binding compounds. This led to the identification of the avermectin macrocyclic lactone derivatives selamectin and ivermectin (Mectizan) as candidate compounds. Both selamectin and ivermectin phenocopied the effects of SID peptide to block SIN3–PAH2 interaction with MAD, induce expression of CDH1 and ESR1, and restore tamoxifen sensitivity in MDA-MB-231 human and MMTV-Myc mouse TNBC cells in vitro. Treatment with selamectin or ivermectin led to transcriptional modulation of genes associated with EMT and maintenance of a cancer stem cell phenotype in TNBC cells. This resulted in impairment of clonogenic self-renewal in vitro and inhibition of tumor growth and metastasis in vivo. Underlining the potential of avermectins in TNBC, pathway analysis revealed that selamectin also modulated the expression of therapeutically targetable genes. Consistent with this, an unbiased drug screen in TNBC cells identified selamectin-induced sensitization to a number of drugs, including those targeting modulated genes. Mol Cancer Ther; 14(8); 1824–36. ©2015 AACR.

1 January 2016
Verified
Book Chapter
Closed access
NBNidhi Bansal
Nidhi Bansal
GDG. David
G. David
EFE. Farias
E. Farias
SWSamuel Waxman
Samuel Waxman

2 December 2018 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
EPEric M. Prager
Eric M. Prager
KCKaren E. Chambers
Karen E. Chambers
JPJoshua L. Plotkin
Joshua L. Plotkin
DMDavid L. McArthur
David L. McArthur
ABAnita Bandrowski
Anita Bandrowski
CGChris Graf
Chris Graf
Progress in basic and clinical research is slowed when researchers fail to provide a complete and accurate report of how a study was designed, executed, and the results analyzed. Publishing rigorous scientific research involves a full description of the methods, materials, procedures, and outcomes. Investigators may fail to provide a complete description of how their study was designed and executed because they may not know how to accurately report the information or the mechanisms are not in place to facilitate transparent reporting. Here, we provide an overview of how authors can write manuscripts in a transparent and thorough manner. We introduce a set of reporting criteria that can be used for publishing, including recommendations on reporting the experimental design and statistical approaches. We also discuss how to accurately visualize the results and provide recommendations for peer reviewers to enhance rigor and transparency. Incorporating transparency practices into research manuscripts will significantly improve the reproducibility of the results by independent laboratories.